Interleukin-17A (IL-17A) is a pro-inflammatory cytokine with well-characterized biological effects on stromal cell activation, angiogenesis, and osteoclastogenesis. The presence of this cytokine in the inflamed joints of patients with rheumatoid arthritis (RA), together with compelling data from in vitro and experimental arthritis models demonstrating its pro-inflammatory effects, made this cytokine a strong candidate for therapeutic targeting. Clinical trials, however, have shown relatively modest success in RA as compared with other indications. Guided by recent insights in IL-17 biology, this review aims to explore possible reasons for the limited clinical efficacy of IL-17A blockade in RA, and what we can learn from these results going forward.

中文翻译：

---

Interleukin-17 在类风湿性关节炎中的作用：考验与磨难

白细胞介素-17A (IL-17A) 是一种促炎细胞因子，对基质细胞活化、血管生成和破骨细胞生成具有明确的生物学效应。这种细胞因子存在于类风湿性关节炎 (RA) 患者的发炎关节中，加上来自体外和实验性关节炎模型的令人信服的数据证明了其促炎作用，使得这种细胞因子成为治疗靶向的有力候选者。然而，与其他适应症相比，临床试验显示在 RA 方面取得的成功相对有限。在 IL-17 生物学的最新见解的指导下，本综述旨在探讨 IL-17A 阻断在 RA 中临床疗效有限的可能原因，以及我们可以从这些结果中学到什么。